Efficacy and Tolerability of First-Line Triple Therapy With Levofloxacin and Amoxicillin Plus Esomeprazole or Rabeprazole for the Eradication of Helicobacter pylori Infection and the Effect of CYP2C19 Genotype: A 1-Week, Randomized, Open-Label Study
Efficacy and Tolerability of First-Line Triple Therapy With Levofloxacin and Amoxicillin Plus Esomeprazole or Rabeprazole for the Eradication of Helicobacter pylori Infection and the Effect of CYP2C19 Genotype: A 1-Week, Randomized, Open-Label Study
复制标题
左氧氟沙星和阿莫西林加埃索美拉唑或雷贝拉唑一线三联疗法根除幽门螺杆菌感染的疗效和耐受性以及 CYP2C19 基因型的影响：一项为期 1 周、随机、开放标签的研究
作者：
Pan, Xiaolin;Li, Yuqing;Qiu, Yuping;Tang, Qiyun;Qian, Bingbing;Yao, Linhua;Shi, Ruihua;Zhang, Guoxin
